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Abstract: Prostate cancer is the second leading cause of cancer death among men in the United States of America. However, 
the molecular mechanisms underlying the disease remain largely unknown. Therefore, the identiﬁ  cation of tumor speciﬁ  c 
molecules that serve as targets for the development of new cancer drugs is considered to be a major goal in cancer research. 
The mouse Engrailed-2 (En-2) gene, which is a homeobox-containing transcription factor was recently identiﬁ  ed as a can-
didate oncogene in breast cancer. Here, we demonstrate that En-2 is over-expressed in human prostate cancer cells as 
compared to normal prostate epithelial cells. In addition, our data suggests that EN2 expression may be positively modulated 
by PAX2 transcription factor. Furthermore, down-regulation of EN2 expression by siRNA resulted in a decrease in PAX2 
expression. We also provide evidence that down-regulation of EN2 expression causes a dramatic decrease in prostate cancer 
cell proliferation. Therefore, from our studies we conclude that En-2 is a candidate oncogene in prostate cancer and its 
PAX2-regulated expression contributes to prostate cancer cell growth.
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Introduction
Prostate cancer is the most common non-cutaneous neoplasm and the second leading cause of male 
death in the United States (Jemal et al. 2006). The incidence of prostate cancer is known to increase 
with age. In addition, multiple genetic and epigenetic factors have been implicated in the oncogenesis 
of prostate cancer, although the molecular mechanisms underlying the disease remain largely unknown 
(Bostwick and Qian, 1994; Grizzle et al. 1994). Therefore, identiﬁ  cation of genetic alterations and genes 
associated with the development and progression of prostate cancer is important to the understanding 
of the disease (Kallioniemi and Visakorpi, 1996). Developmental genes that encode transcription factors 
have an important role in the regulation of speciﬁ  c genes and are necessary for normal growth. In addi-
tion, it has been revealed that aberrant expression and structural alteration of transcription factors are 
often primary molecular mechanisms in tumorigenesis (Rabbitts, 1994).
PAX (paired) genes, a family of developmental control genes and transcription factors, regulate tis-
sue development and cellular differentiation in embryos by promoting cell proliferation, migration and 
survival (Wallin et al. 1998; Buttiglieri et al. 2004; Gnarra and Dressler, 1995). PAX2 (paired box 2), a 
class III PAX gene, has been shown to be expressed in the developing central nervous system, eye, ear 
and urogenital tract (Gruss and Walther, 1992; Dressler et al. 1990). Our previous studies demonstrated 
that PAX2 expression is an essential requirement for prostate cancer cell survival (Gibson et al. 2007). 
Furthermore, PAX genes have been shown to be capable of acting as proto-oncogenes by transactivating 
promoters of target genes involved in the regulation of cell growth and apoptosis (Stuart et al. 1995). 
Therefore, these transcription factors can function both as activators and repressors of transcription.
Another gene class that functions as a homeobox containing transcription factor is the mouse 
engrailed-2 (En-2), which is the murine homologs of the Drosophila segment polarity gene (En) 
(McMahon et al. 1992). It has been observed that PAX and En genes are the part of genetic networks 
that control the development of brain and occupy a prominent position in the developmental regulatory 
hierarchy (Joyner, 1996). Previous reports revealed that EN2 expression is deregulated in pediatric brain 
tumor and acute myeloid leukemia (AML) (Kozmik et al. 1995; Nagel et al. 2005). Although En-2 was 
recently identiﬁ  ed as a candidate oncogene in human breast cancer, very little is known about this 
regulatory gene relative to organogenesis and cancer (Martin et al. 2005). In the present work, we 38
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provide evidence that EN2 is aberrantly expressed 
in prostate cancer and is regulated by the PAX2 
transcription factor that promotes prostate cancer 
cell growth and survival. Furthermore, we found 
a positive correlation between En-2 and PAX2 
genes in prostate cancer cell lines, where cells 
exhibiting decreased EN2 expression also exhibited 
a down regulation of PAX2 expression level.
Material and Methods
Cell culture
The prostate cancer cell lines were obtained from 
the American Type Cell Culture (ATCC). The 
DU145 were cultured in DMEM medium, PC3 were 
grown in F-12 medium and LNCaP were grown in 
RPMI medium (Life Technologies, Inc., Grand 
Island, NY). Growth media for all three lines was 
supplemented with 10% (v/v) fetal bovine serum 
(Life Technologies). The human prostate epithelial 
cell (hPrEC) cells (Cambrex Bio Science Inc.) were 
cultured in prostate epithelium basal media supple-
mented with the SingleQuot
® bullet kit (Cambrex 
Bio Science Inc., Walkersville, MD). All cell lines 
were maintained at 37 °C and 5% CO2.
siRNA silencing of PAX2 and EN2
Small interfering RNA knock-down was performed 
as previously described (Gibson et al. 2007). 
Brieﬂ  y, a pool of four complementary siRNAs, 
targeting human PAX2 mRNA (Accession no. 
NM_003989.1) were synthesized (Dharmacon 
Research, Lafayette, CO, USA) to knock down 
expression. To achieve En-2 gene silencing, siRNA 
targeting human EN2 mRNA (Accession no. 
NM_001427.2) was purchased from Ambion 
(Applied Biosystem, Inc.). In addition, a second 
pool of four non-speciﬁ  c siRNAs was used as a 
negative control (Dharmacon, Inc.). siRNA mol-
ecules were transfected with Code-Breaker trans-
fection reagent according to the manufacturer’s 
protocol (Promega, Inc.).
RNA isolation and quantitative 
real-time PCR
RNA was collected after two to four days of siRNA 
treatment. Approximately 5 × 10
5 cells were tryp-
sinized and harvested by centrifugation at 4000 × g 
at 4 
oC. Cell pellets were washed twice with ice 
cold PBS and total RNA was isolated by using the 
RNAeasy kit (Qiagen Inc., CA, USA). Total RNA 
(0.5 µg per reaction) was reverse transcribed into 
cDNA using random primers (Promega, Madison, 
WI, USA). AMV Reverse Transcriptase II enzyme 
(500 units per reaction; Promega) was used for ﬁ  rst 
strand synthesis and Tﬂ   DNA Polymerase for sec-
ond strand synthesis (500 units per reaction; Pro-
mega) as per the manufacturer’s protocol. In each 
case, 50pg of cDNA was used per PCR reaction. 
Two-step QRT-PCR was performed on cDNA 
generated using the MultiScribe Reverse Tran-
scriptase from the TaqMan Reverse Transcription 
System and the SYBR Green PCR Master Mix 
(Applied Biosystems, Foster City, CA). The primer 
pair for human PAX2 (Cat # PPH06881-A) and 
En-2 (Cat. # PPH00975A) were purchased from 
Super Array Bioscience, MD, USA. Forty cycles 
of PCR were performed under standard conditions 
at an annealing temperature of 55 
oC (ABI Prism 
7000). In addition, GAPDH was ampliﬁ  ed as a 
housekeeping gene to normalize the initial content 
of total cDNA as previously described (Gibson 
et al. 2007). Relative PAX2 and EN2 expression 
levels were calculated by comparing the prostate 
cancer cell lines before and after treatment with 
siRNA to untreated control cells. As a negative 
control, QRT-PCR reactions without cDNA tem-
plate were also performed. All reactions were run 
three times in triplicate.
Cell proliferation assay
The rate of cell proliferation was determined by 
[3H] thymidine ribotide ([3H]TdR) incorporation 
into DNA. Approximately 2.5–5 × 10
4 cells were 
plated onto 24-well plates in their appropriate 
media. Cells were incubated for 72 hours in the 
absence or presence of siRNA at the indicated 
concentrations. The cells were exposed to 37 kBq/
ml [methyl-3H] thymidine in the same medium for 
6 hours. The adherent cells were ﬁ  xed by 5% 
trichloro-acetic acid and lysed in SDS/NaOH lysis 
buffer overnight. Radioactivity was measured with 
a Beckman LS3801 liquid scintillation counter. All 
assays were run three times in triplicate.
Preparation of total cell extract 
and western blotting
Cell treated with siRNA or media only were tryp-
sinized, washed with ice-cold PBS and harvested 
by centrifugation at 100 × g for 5 min at 4 
oC. Cell 39
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pellets were resuspended in a mammalian lysis 
buffer containing 1 mM DTT and protease inhibi-
tor cocktail (Sigma Inc., Saint Louis, MI, USA). 
Lysates were incubated for 15 min on ice followed 
by centrifugation at 12,000 × g for 10 min at 4 
oC 
to produce total cell extract. Total protein recovered 
in the supernatant was estimated by Bio-Rad assay 
and stored in aliquots at −80 
oC.
For Western Blot analysis, 18–25 µg of protein 
sample was mixed with denaturation buffer and 
boiled for 5 min followed by separation on a 
4%–12% NUPAGE Bis-Tris denaturing gel using 
MES- SDS Runnig buffer. Protein was transferred 
from the gel to a PVDF membrane that was then 
blocked for 2–3 hours at room temperature in non-
fat dried milk in TBS-T buffer (10 mM Tris/HCl, 
pH 8.0, 150 mM NaCl and 0.05% Tween-20). Blots 
were probed with either rabbit anti-PAX2 (Zymed, 
Inc.) or goat anti-EN2 antibody (Santa Cruz, Inc.) 
at 1:1000 dilutions overnight at 4 
oC under gentle 
shaking. The unbound antibodies were removed 
by 4 × 10 min washes in TBS-T buffer. Next, the 
membrane was incubated with peroxidase-
conjugated secondary antibody (Pierce, IL, USA) 
for 90 min at room temperature followed by 
4 × 10 min washes with TBS-T buffer. Finally, the 
blot was developed with luminol reagent (Pierce) 
and visualized by autoradiography. As a negative 
control, the blots were striped and re-probed for 
β-actin as a housekeeping gene. Gel quantiﬁ  cation 
was performed using Image J analysis. Each 
experiment was performed in triplicate.
Statistical analysis
Statistical analysis was performed using the Stu-
dent’s t-test for unpaired values. P values were 
determined by a two-sided calculation, and a 
P value of less than 0.05 was considered statisti-
cally signiﬁ  cant. Statistical differences are indi-
cated by asterisks.
Results
Analysis of EN2 expression 
in prostate cancer cells
To investigate EN2 expression, QRT-PCR was 
performed on prostate cancer cell lines and hPrEC 
prostate primary culture. The EN2 mRNA expres-
sion was 2.15-fold higher in DU145, 30-fold higher 
in PC3 and 7.8-fold higher in LNCaP compared to 
hPrEC cells (Fig. 1A). EN2 protein level was 
examined by Western Blot (Fig. 1B). Our data 
revealed low levels of EN2 protein in hPrEC cells 
(lane 3). However, EN2 was over-expressed in all 
of the prostate cancer cell lines. Here EN2 expres-
sion was lowest in DU145, while PC3 cells pos-
sessed the greatest amount of expression. EN2 
expression was 8-fold higher in PC3 (lane 1), 
6-fold higher in LNCaP (lane 2) and 4-fold higher 
in DU145 (lane 4) prostate cancer cells compared 
to hPrEC cells.
Small interfering RNA-mediated 
suppression of EN2
QRT-PCR analysis of EN2 expression was moni-
tored in PC3 cells following treatment with EN2 
siRNA. This study revealed a 63% decrease after 
48 hours, 43% after 72 hours, and 60% after 96 
hours of En-2 siRNA treatment in PC3 (Fig. 2A). 
Western Blot analysis was performed to monitor 
changes in EN2 protein levels after selective target-
ing and inhibition by En-2 speciﬁ  c siRNA in PC3 
prostate cancer cells. Following treatment, protein 
expression decreased by 70% at 48 hours, 20% at 
72 hours and 26% at 96 hours (Fig. 2B). Efﬁ  ciency 
Figure 1. Analysis of EN2 expression in prostate cells.
A) EN2 mRNA level were examined by QRT-PCR in hPrEC prostate 
primary epithelial cells and in DU145, PC3 and LNCaP prostate 
cancer cells. EN2 mRNA levels were signiﬁ  cantly higher in PC3, 
LNCaP and DU145 than hPrEC cells. B) Western blot analysis of 
EN2 was performed on PC3 (lane 1) and LNCaP (lane 2), hPrEC 
(lane 3) and DU145 (lane 4) cells. EN2 protein levels was highest in 
PC3 cells. β-actin was used as an internal control to ensure equal 
loading.
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of EN2 knock-down was compared in PC3 and 
LNCaP cell lines (Fig. 2C). After siRNA treatment 
for 72 hours, EN2 protein levels decreased by 25% 
in PC3 (lane 2), and by 60% in LNCaP (lane 4) 
when compared to untreated PC3 (lane 1) and 
LNCaP (lane 3) cells.
Effect of EN2 knockdown on prostate 
cancer cell growth
To examine the effect of therapeutic targeting and 
inhibition of EN2 expression on the rate of prostate 
cancer cell growth, cell proliferation was moni-
tored by a thymidine incorporation assay after 72 
hours of siRNA treatment against En-2 in PC3 and 
LNCaP cells. Treatment of PC3 cells with 150 nM 
EN2 siRNA resulted in a 20% inhibition in cell 
proliferation rate compared to cell treated with 
media only (Fig. 3). However, treatment of LNCaP 
cells with En-2 siRNA resulted in an 81% decrease 
in proliferation rate as compared to those treated 
with the non-speciﬁ  c siRNA. As a negative control, 
cells were treated with an equal amount of non-
specific siRNA, and there was no significant 
change in cell viability.
Effect of PAX2 knockdown on EN2 
expression in prostate cancer
To determine the role of PAX2 on EN2 expression 
in prostate cancer, PC3 and LNCaP cells were 
treated for 3 days with a pool of siRNA speciﬁ  cally 
targeted against PAX2. We previously demonstrated 
that siRNA knockdown of PAX2 expression occurs 
as early as 2 days in the prostate cancer cell lines 
(Gibson et al. 2007). QRT-PCR analysis revealed 
that EN2 mRNA level was down-regulated in PC3 
cell line by 91% as compared to control cells 
treated with media only (Fig. 4A). In addition, EN2 
mRNA in LNCaP cells was suppressed by 23% 
compared to control. Western blot analysis of EN2 
protein expression in the prostate cancer cell lines 
after 3 days of PAX2 siRNA treatment (Fig. 4B) 
demonstrated that EN2 expression was decreased 
70% in PC3 (lane 2) and 26% in LNCaP (lane 4) 
prostate cancer cell lines as compared to PC3 
(lanes 1) and LNCaP (lanes 3) controls.
Analysis of PAX2 expression after 
EN2 knockdown in prostate cancer
QRT-PCR analysis of PAX2 was performed in 
LNCaP cells after treatment with EN2 siRNA to 
determine whether En-2 can modulate PAX2 
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Figure 2. Silencing of EN2 expression after En-2 siRNA treatment.
A) QRT analysis of EN2 mRNA levels reveal a signiﬁ  cant decrease 
in expression during 48–96 hours of En-2 siRNA treatment as com-
pared to control. B) Western blot analysis of EN2 protein levels in 
PC3 show a decrease in expression following siRNA treatment dur-
ing 48 hours to 96 hours of siRNA treatment compared to untreated 
cells. C) Efﬁ  ciency of EN2 knock-down showed signiﬁ  cant down-
regulation of EN2 after 72 hours of siRNA treatment in PC3 (lane 2) 
and LNCaP (lane 4) compared to untreated PC3 (lane 1) and LNCaP 
(lane 3). β-actin was used as an internal control to ensure equal 
loading.
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Figure 3. Analysis of prostate cancer cell growth after EN2 siRNA 
treatment.
PC3 and LNCaP prostate cancer cells were treated with 150 nM of 
En-2 siRNA or non-speciﬁ  c negative control siRNAs for 3 days after 
which cell proliferation was examined by thymidine incorporation 
assay. Cell proliferation was decreased by 20% in PC3 and 80% in 
LNCaP cells.41
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expression in prostate cancer. Our data revealed 
that PAX2 mRNA level was signiﬁ  cantly decreased 
by 90% at 48 hours, 67% at 72 hours and 90% at 
96 hours in LNCaP cells (Fig. 5A). Furthermore, 
to test the correlation between PAX2 and EN2 at 
the protein level, Western blot analysis was per-
formed. Here, PAX2 protein level decreased by 
50% at 48 hours (lane 3), by 66% at 72 hours 
(lane 4) and by 72% at 96 hours (lane 5) after En-2 
siRNA treatment compared to untreated cells 
(lane 1) and non-specific siRNA treated cells 
(lane 2) (Fig. 5B).
Discussion
There is considerable heterogeneity in the 
biological aggressiveness of prostate cancer. 
Therefore, the identiﬁ  cation of reliable diagnostic 
and/or prognostic markers and the development of 
novel mechanism-based therapeutic treatment 
regimens are urgently needed (Tang and Porter, 
1997). It has been reported that the relationship 
between developmental processes and oncogenesis 
involves deregulated cell growth (Kallioniemi and 
Visakorpi, 1996). The En-1 and En-2 genes, 
homologues of the mouse and drosophila 
segmentation gene engrailed (En), encode 
homeodomain transcription factors (Joyner, 1996). 
Little is known about the role of engrailed genes 
in tumorogenesis. In 2005, Martin et al. provided 
the ﬁ  rst evidence of En-2 as a candidate oncogene, 
which is aberrantly expressed in breast cancer and 
has a role in mammary tumorigenesis. EN2 was 
also detected in SAGE libraries derived from 
human brain glioblastoma, colon and ovarian car-
cinomas (Martin et al. 2005). Here we demon-
strated that EN2 is over-expressed in human 
prostate cancer cells compared to normal prostate 
epithelial cells (Fig. 1). Therefore, our data sug-
gests that EN2 is over-expressed in prostate cancer 
and may contribute to prostate tumorigenesis.
In this study we examined the role of EN2 over-
expression in the following prostate cancer cell 
lines: LNCaP, which is p53 wild-type and androgen 
receptor (AR) positive; DU145, which has a 
mutated p53 and is AR negative; and the p53-null 
line PC3, which is also AR negative. EN2 expres-
sion was highest in PC3 cells compared to the other 
two lines with the greatest difference existing 
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Figure 4. Analysis of EN2 expression after PAX2 siRNA treatment.
A) EN2 mRNA expression was examined after 72 hours of PAX2 
siRNA treatment of PC3, as well as, LNCaP prostate cancer cell lines 
by QRT-PCR. Treatment with PAX2 siRNA resulted in a dramatic 
decrease in EN2 expression in PC3 cells and a modest decrease in 
LNCaP. B) Western blot analysis of EN2 protein expression revealed 
a 70% decrease in protein levels in PC3 after 72 hours PAX2 siRNA 
treatment (lane 2) compared to untreated PC3 cells (lane 1). In 
LNCaP there was a 26% decrease in EN2 protein levels after PAX2 
siRNA (lane 4) compared to untreated control cells (lane 3). β-actin 
was used as an internal control to ensure equal loading.
Figure 5. Analysis of PAX2 expression after EN2 knockdown in 
prostate cancer cells.
A) QRT-PCR was performed to examine PAX2 mRNA levels in the 
LNCaP prostate cancer cell line after En-2 siRNA treatment. Follow-
ing treatment with En-2 siRNA, PAX2 expression levels decreased 
by 60–90% during 48–96 hours. Data is presented as relative expres-
sion compared to untreated LNCaP cells. B) Examination of PAX2 
protein levels in LNCaP after En-2 siRNA treatment by Western blot 
analysis revealed a signiﬁ  cant decrease during 48 hours to 96 hours 
(lanes 3–5) compared to untreated cells (lane 1). As a negative 
control, PAX2 expression was also tested in presence of non-speciﬁ  c 
siRNA (lane 2). β-actin was used as an internal control to ensure 
equal loading.
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between PC3 and LNCaP. This finding was 
particularly interesting given that LNCaP cells are 
relatively slow-growing and are thought to repre-
sent early-stage prostate cancer, while PC3 cells 
are fast-growing and are thought to represent late-
stage, aggressive prostate cancer. Previous studies 
have demonstrated that the suppression of EN2 in 
breast cancer cell lines by siRNA against En-2 
resulted in a signiﬁ  cant decrease in their prolifera-
tion rate (Martin et al. 2005). Here we found a 
similar response in prostate cancer cells (Fig. 3). 
These ﬁ  ndings are in line with our previous obser-
vation that siRNA knockdown of PAX2 resulted in 
dramatic decreases in prostate cancer cell growth 
(Gibson et al. 2007). In addition, PAX2 expression 
levels were found to be signiﬁ  cantly higher in PC3 
cell line compared to LNCaP cells. Given that sup-
pression of EN2 results in the down-regulation of 
PAX2 expression, this observation may be due to 
the reactivation of anti-proliferative factors that 
are negatively regulated by PAX2 such as p53. 
This further implicates En-2 as a therapeutic target 
for cancer either directly or indirectly via target-
ing PAX2.
To date, little is known about the factors that 
regulate EN2 expression. Studies in drosophila, 
zebra fish and mice indicate that the PAX-En 
genetic pathway is conserved during evolution and 
they interact with each other (Song et al. 1996). 
PAX2, a member of the PAX gene family of tran-
scriptional regulators, is essential during early 
development of the urogenital system (Eccles et al. 
2002). In addition, PAX2 has been shown to be 
aberrantly over-expressed in urogenital cancers, 
including prostate carcinomas (Discenza et al. 
2003; Khoubehi et al. 2001; Muratovska et al. 
2003). Studies have shown that PAX2 expression 
in malignant cells generates a proliferation stimu-
lus, that may be an integral part of the multi-step 
oncogenic transformation process (Gibson et al. 
2007). PAX2 contains novel recognition sequences 
within the paired domain and activating domains 
within the C-terminal region that facilitate repres-
sion and activation of gene transcription through 
DNA binding (Havick et al. 1999). PAX2 has also 
been shown to interact with the tumor suppressor 
genes WT1 and p53 (Stuart et al. 1995; Dehbi et al. 
1996).
Here we have demonstrated that suppression of 
PAX2 expression by siRNA resulted in a decrease 
in En-2 gene expression. These ﬁ  ndings suggest 
that PAX2 may be a transcriptional activator of 
En-2 although this was not examined in this study. 
Furthermore, we found a positive correlation 
between EN2 and PAX2 where prostate cancer cells 
exhibiting decreased EN2 expression also pos-
sessed decreased PAX2 levels. This indicates that 
EN2 expression may inﬂ  uence PAX2 through a 
feedback mechanism. Taken together, it is plau-
sible that deregulated expression of PAX2 and EN2 
may ultimately promote tumor progression spe-
cifically via cancer cell proliferation and sur-
vival.
Although there have been signiﬁ  cant advances 
made in cancer therapeutics, little progress has 
been made in the treatment of the advanced stage 
of cancers. Successful drug treatment of prostate 
cancer requires the use of therapeutics with spe-
ciﬁ  c effects on target cells with overall aim of 
inducing apoptosis while maintaining minimal 
clinical effects on the host. Here we demonstrate 
that En-2 may contribute to the process of onco-
genesis by conferring a growth advantage to 
prostate cancer cells by supporting cellular pro-
liferation. Collectively, our data suggest that En-2 
may prove useful as a speciﬁ  c biomarker marker 
of prostate malignancy and further investigation 
may explain its mechanistic contribution to the 
tumorigenic process.
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